[Behavior of brain perfusion with SPECT tomography 99mTc ethylene dicysteine (ECD) in alcohol and cocaine dependents during abstinence].
Brain perfusion abnormalities after an abstinence period of 28 days in a group of patients with alcohol and / or cocaine dependence was investigated. They were related with gender, consumption period and number of drugs. Fifty men and 10 women were included and SPECT perfusion was performed using 99mTc ethylene cysteine dimer (ECD) with qualitative and semiquantitative section analysis. Perfusion abnormalities were observed in 60% of the patients, principally in frontal, temporal and parietal lobes. The abnormalities were focal in 58.3%, diffuse in 41.7% and bilateral in 95% of all patients. Abnormalities were observed in 68% of the men and in only 20% of the women (p = 0.01). Patients with brain perfusion abnormalities had a longer period of consumption corresponding to a median of 17.5 years in patients with abnormalities versus nine years in those with no abnormalities (p = 0.036), however, their ages as well as the number of drugs consumed were not significantly different. In conclusion, after 28 days of alcohol and / or cocaine abstinence there is significant presence of brain perfusion abnormalities with 99mTc ECD. This could be explained by vasospasm and / or secondary endothelial lesions.
Pallavicini González
J
J
Departamento de Psiquiatría y Salud Mental y Centro de Medicina Nuclear del Hospital Clínico Universidad de Chile. Facultad de Medicina. Universidad de Chile. jpallavi@ns.hospital.uchile.cl
Massardo Vega
T
T
Arancibia Soto
P
P
González Espinoza
P
P
Cumsille Garib
F
F
Padilla Padilla
P
P
D000293:Adolescent; D000328:Adult; D000437:Alcoholism / Q000000981:diagnostic imaging* / Q000503:physiopathology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003042:Cocaine / Q000009:adverse effects; D019970:Cocaine-Related Disorders / Q000000981:diagnostic imaging* / Q000503:physiopathology; D003545:Cysteine / Q000031:analogs & derivatives*; D000431:Ethanol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D013375:Substance Withdrawal Syndrome / Q000000981:diagnostic imaging* / Q000503:physiopathology; D015899:Tomography, Emission-Computed, Single-Photon; D020301:Vasospasm, Intracranial / Q000139:chemically induced / Q000000981:diagnostic imaging
D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C073806:technetium Tc 99m-ethylenedicysteine; D000431:Ethanol; D003042:Cocaine; D003545:Cysteine